Thomas Flaig is an Oncology physician affiliated with University of Colorado Cancer Center. OpenAlex indexes 396 publications with 23,425 citations (h-index 54); ClinicalTrials.gov lists 5 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 3 Oct 2012.
Clinical trials
- Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
Sponsor: University of Colorado, Denver
- S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
Sponsor: SWOG Cancer Research Network
- Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
Sponsor: University of Colorado, Denver
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TAIHO ONCOLOGY, INC.Program year20254 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20246 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2010–2011 per NIH RePORTER. The latest:
- Targeted nanoparticle thermoablation for the treatment of bladder cancer
University of Colorado Denver
FY2011$153,753R21CA152375 - Targeted nanoparticle thermoablation for the treatment of bladder cancer
University of Colorado Denver
FY2010$196,333R21CA152375
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Journal of the National Comprehensive Cancer Network
2022 - Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Wells Messersmith, MD
University of Colorado Cancer Center
Manali Kamdar, MD
University of Colorado Cancer Center
Bryan Haugen, MD
University of Colorado Cancer Center
Christopher Lieu, MD
University of Colorado Cancer Center
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”